Microplate-based automatic blood grouping analyzer Metis of Aikang MedTech Co., Ltd. (henceforth referred to as Aikang) received approval for marketing in 2015; and its MGT-based automatic blood grouping analyzer Aigel received approval for marketing in 2016.

Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

Recently, MGI and Singapore biotechnology company MiRXES Pte Ltd. (MiRXES) officially reached a strategic partnership.

LumiraDx said on Wednesday that it has received CE marking for a molecular SARS-CoV-2 test and an assay that tests for both SARS-CoV-2 and influenza virus.

Becton Dickinson and CerTest Biotec will collaborate to develop an RT-PCR-based diagnostic test for monkeypox to run on the BD Max System, they announced on Wednesday.

R-Biopharm said on Tuesday that it has acquired AusDiagnostics, an Australian maker of multiplexing molecular diagnostic assays and reagents.

The US Food and Drug Administration last week granted DxLab Emergency Use Authorization for its molecular DxLab COVID-19 test.

The Construction of Mindray, Biotime and Nanomicro R&D Bases Begins

Recently, Fosun Pharma is planning to incorporate OncoCare, one of the largest private oncology medical centers in Singapore.

By the year 2030, pancreatic cancer is expected to become the second most common cause of cancer deaths for both men and women in the United States, according to recent reports. While considered uncommon, inherited gene mutations can increase a person’s risk of developing pancreatic cancer.

Pfizer Inc. announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Michigan, facility, enabling U.S.-based production in support of its COVID-19 oral treatment.

GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced a broad strategic collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and commercialize companion diagnostic (CDx) assays for use with AstraZeneca’s therapies.